title: [Evaluation of cardiovascular risk in the longitudinal phase of the Mediterranean study].
abstract: OBJECTIVE
  There is little information on cardiovascular longitudinal studies. In Spanish patients with hypertension (AHT)) and/or hypercholesterolemia (HC), with poor initial control of blood pressure (BP) and/or total cholesterol (TC), incidence rate (IR), cumulative incidence (CI), relative risks (RR), survival curves (SC), therapeutic compliance (TC) were quantified and the Framingham-Anderson scale (FAS) was adjusted to our patients.
  
  
  METHODS
  A total of 6,893 primary prevention patients with AHT and/or with HC were included in primary prevention, with an average of 1.22 years of follow-up. A total of 480 physicians participated. Incidence rate (IR), cumulative incidence (CIN), relative risks (RR), survival curves (SC) by Kaplan-Meier method, and therapeutic compliance (TCOM) by Haynes-Sackett self-reported questionnaire were calculated. The Framingham-Anderson scale (FAS) was validated with Pearson's correlation coefficient (r) and intraclass correlation index (ICI).
  
  
  RESULTS
  CIN was 1.59% (1.31-1.90); the IR 1,321.6 cardiovascular events/ 100,000 patients/year (1,026.6-1,598.8). RRs with statistical significance were: age (p = 0.03). Blood pressure at the end of the study (p = 0.02), coronary background (p = 0.00), left ventricular hypertrophy (LVH) (p = 0.00), microalbuminuria (p = 0.02), CT >/= 250 mg/dl (p = 0.01), fasting glycemia (Gb) >/= 126 mg/dl (p = 0.00), creatinine >/= 1.2 mg/dl at the beginning (p = 0.00) and at the end of the study (p = 0.00), and poor compliance in HC patients (p = 0.00). SC have statistical significance (p < 0.05) for AHT background, fasting glucose >/= 126 mg/dl, target organ damage, and high cardiovascular risk with FAS scale. The adjusted FAS formula for global cardiovascular risk was (0.415 x FAS Risk%) + 0.517%, r = 0.9962 (p = 0.00) and ICI = 0.9969 (p < 0.0001).
  
  
  CONCLUSIONS
  The equation for the FAS scale was adjusted for Spanish AHT/HC patients. Prognostic factors and SC were calculated. Benefit between TC and decrease of CVR in HC patients was quantified.
authors.affiliation: REDIAPP-CV. Unidad de Investigación. Docencia y Práctica Clínica departamento 18 CV. Universidad Miguel Hernández. Elche. Alicante. España. atención.primaria@umh.es
authors.forename: V F
authors.initials: VF
authors.lastname: Gil-Guillén
authors.forename: J
authors.initials: J
authors.lastname: Merino-Sánchez
authors.forename: T
authors.initials: T
authors.lastname: Sánchez-Ruiz
authors.forename: T
authors.initials: T
authors.lastname: Amorós-Barber
authors.forename: J
authors.initials: J
authors.lastname: Aznar-Vicente
authors.forename: J
authors.initials: J
authors.lastname: Abellán-Alemán
authors.forename: J L
authors.initials: JL
authors.lastname: Llisterri-Caro
authors.forename: D
authors.initials: D
authors.lastname: Orozco-Beltrán
authors.forename: M
authors.initials: M
authors.lastname: Pascual Pérez
authors.forename: E
authors.initials: E
authors.lastname: Márquez Contreras
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015996:Survival Rate